Halaven (eribulin mesylate)

An ALC ≥ 1000/μL at ERI completion was associated with an improved post-ERI OS (OS2). It is suggested that not only the factors at the initiation of ERI, but also the immunological status at the end of ERI, may have prognostic value after ERI.

P=N/A, N=35, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital

P3, N=120, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P2, N=33, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital

P2, N=50, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

P3, N=200, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

P3, N=644, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Nov 2028

P3, N=350, Active, not recruiting, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting

We separately described outcomes and treatment patterns of patients with resectable and unresectable RPS. Our findings suggest that eribulin should be considered a treatment option for unresectable RPS in clinical practice.

Moreover, BB-1701, a novel HER2-ADC containing eribulin as a payload, to which N87 AR cells are sensitive, exhibited antitumor effects in N87 AR cells in vitro and in vivo. These findings indicate that ABC transporter-mediated drug efflux is an important mechanism underlying T-DXd resistance in HER2-positive gastric and lung cancer models. Furthermore, our study suggests that both targeting drug efflux pathways and utilizing alternative payloads may be effective strategies for overcoming T-DXd resistance in HER2-positive gastric and lung cancers.

P2, N=24, Active, not recruiting, University of Miami | Recruiting --> Active, not recruiting | N=500 --> 24

P2, N=35, Not yet recruiting, Xijing Hospital